NPHS1 and Parkinson disease: The currently ongoing first in-man proof-of-concept trial (see “Footnote 1”; DBS-SCI, Identifier: NCT03053791) investigating the potential of CnF-DBS to improve gait in chronic incomplete spinal cord injured patients as well as the clinical trial investigating the CnF as therapeutic target to relieve levodopa-resistant freezing of gait in patients suffering from Parkinson’s Disease (see “Footnote 1”; DBS + FOG, Identifier: NCT04218526) are expected to generate further important information on the therapeutic potential of CnF-DBS for gait deficiency in human patients.